About MolMed
MolMed is a Healthcare company based in Milano (Italy) founded in 1996, and was acquired by AGC Biologics in July 2020. It operates as a developer of gene and cell therapies for the treatment of cancer and rare diseases. The company was acqui-hired. MolMed offers products and services including CAR-T Platform, CAR-NK, Viral Vectors, and Genetically Modified Cells. Its focus areas include Life Sciences, Immunotherapy, Adoptive Cell Therapy and T-Cell. Its legal entity is MolMed S.p.A. Its competitors include Jazz Pharmaceuticals, Insitro, BridgeBio, Celgene and ATAI and 3 more; 8 of its 8 listed competitors have raised funding.
Company details
MolMed was founded in 1996 in Milano, Italy, within the biotechnology sector. Gene and cell therapies are developed by the company to address cancer and rare diseases. The pipeline features Zalmoxis (TK), a cell-based treatment for acute leukemia; NGR-hTNF, targeted at solid tumors; and CAR-CD44v6, an immuno-gene therapy for hematological malignancies and various epithelial tumors. Operations center on advancing these therapeutic innovations.
- Headquarters Milano, Italy
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website molmed.com
- Social LinkedIn
- Acquired by AGC Biologics (Jul 2020)
- Legal Name Molmed S.P.A.
- Latest Funding Round$2.1M (USD), Grant
Jan 2017
- InvestorsEuropean Union
& 1 more
- Acquired byAGC Biologics
(Jul 2020)
Products & Services of MolMed
MolMed offers a comprehensive portfolio of products and services, including CAR-T Platform, CAR-NK, Viral Vectors, and Genetically Modified Cells.
Develops therapies using genetically modified T cells for cancer.
Provides treatments with modified natural killer cells for oncology.
Enables gene delivery for research and clinical applications.
Supports production of customized cells for therapy development.
Funding Insights of MolMed
- Total Rounds 1
- Last Round Grant — $2.1M
- First Round $2.1M
(Jan 2017)
- Investors Count 1
All 1 funding rounds of MolMed with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2017 | $2.1M | Grant | – | – |
2 investors in total: 2 institutional.
Investors in MolMed
MolMed has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include European Union and AGC Biologics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Provides contract development and manufacturing for biopharmaceuticals worldwide. | 2018 | agcbio.com | Bothell, United States |
Investor details for MolMed
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MolMed
17 people are tracked at MolMed (4 in leadership, 12 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Salvatore Calabrese | Chief Financial Officer | Leadership |
Riccardo Palmisano | CEO | Leadership |
Enrico Cappelli | Chief Financial Officer | Leadership |
Marina Del Bue | General Manager, Business and Administration | Leadership |
Claudio Bordignon | Founder & SAB President | Board & advisors |
Malcolm K. Brenner | Scientific Advisor | Board & advisors |
Sabina Grossi | Director | Board & advisors |
Gian Pietro Dotti | Scientific Advisor | Board & advisors |
Mohamad Mohty | Scientific Advisor | Board & advisors |
Miguel-Angel Perales | Scientific Advisor | Board & advisors |
David Kauffmann | Director | Board & advisors |
Mario Masciocchi | Independent Director | Board & advisors |
Patricio Massera | Director | Board & advisors |
Tomoko Miyagawa | Director | Board & advisors |
Raffaella Ruggiero | Independent Director | Board & advisors |
Noriyuki Komuro | Chairman of the Board | Board & advisors |
Scialini Colombi | Clinical operations Manager | Team |
Complete people profiles for MolMed
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of MolMed
3 dated milestones of MolMed across 24 years, from founding to its latest funding, stage changes and deals.
- Founded MolMed is founded.
- Funding First funding round of $2.1M.
- Exit Acquired by AGC Biologics.
Competitors of MolMed
MolMed has 8 listed competitors in our database, 8 of them funded. They include Jazz Pharmaceuticals, Insitro, BridgeBio, Celgene and ATAI, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| celgene.com | 1986 | Summit, United States | $45M | 4,891 | Therapies for cancer and inflammatory diseases are developed. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of MolMed
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as MolMed (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Molmed
Complete news archive for MolMed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MolMed
MolMed was founded in 1996 and raised its 1st funding round 21 years after it was founded.
MolMed is headquartered in Milano, Italy.
MolMed was founded in 1996 in Milano, Italy, within the biotechnology sector. Gene and cell therapies are developed by the company to address cancer and rare diseases. The pipeline features Zalmoxis (TK), a cell-based treatment for acute leukemia; NGR-hTNF, targeted at solid tumors; and CAR-CD44v6, an immuno-gene therapy for hematological malignancies and various epithelial tumors. Operations center on advancing these therapeutic innovations.
MolMed's top competitors include Jazz Pharmaceuticals, Spark Therapeutics and BridgeBio.
MolMed offers CAR-T Platform, CAR-NK, Viral Vectors, and Genetically Modified Cells.
MolMed has 2 investors. Key investors include European Union, and AGC Biologics.
MolMed operates through Molmed S.P.A..
Yes. MolMed was acquired by AGC Biologics in July 2020.